A recently published study used thrombelastometry, plasmatic coagulation parameters and platelet count to assess the coagulation system in septic patients before and during a short-term antithrombin therapy. ❋ David R. Altmann Et Al. (2010)
The European Medicines Evaluation Agency (EMEA) may decide early next year on approval of an anticoagulant protein, human antithrombin, that is produced in goat's milk to treat a hereditary disorder. ❋ Unknown (2009)
And certainly this choice of caprine platform has paid off enormously; GTC can now boast a historical milestone with the release of "ATryn®, our recombinant form of human antithrombin, the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures," according to a company statement. ❋ Unknown (2007)
Atryn will be marketed by Ovation Pharmaceuticals Inc., a closely held company in Deerfield, Ill. GTC Biotherapeutics estimates that about 1 in 2,000 to 5,000 people in the U.S. have an inherited antithrombin deficiency. ❋ Unknown (2009)
Scientists at GTC Biotherapeutics, in Framingham, Mass., took DNA responsible for making human antithrombin and inserted it into goat embryos and established a small herd. ❋ Unknown (2009)
The drug, Atryn, developed by GTC Biotherapeutics Inc. from the milk of a genetically altered goat, will be used to treat patients with a rare blood-clotting disorder known as hereditary antithrombin deficiency. ❋ Unknown (2009)
Atryn's approval comes about a month after an FDA panel unanimously said Atryn was safe and effective in preventing life-threatening blood clots in certain patients who lack normal levels of antithrombin. ❋ Unknown (2009)
It is an immunologic attack in which the antigen is a heparin-platelet factor 4 complex which when linked with an IgG antibody activates and aggregates platelets which form microparticles and induces a thrombin storm of coagulation which must be treated by stopping the heparin and giving antithrombin agents. ❋ James Gaulte (2007)
The liver also produces the blood clotting agent prothrombin as well as two anticoagulants, heparin and antithrombin. ❋ JOHN LUST (2003)
ATryn (R), GTC's recombinant human antithrombin, has been approved for use in the United States and Europe. ❋ Unknown (2010)
Lundbeck Inc., to develop a protocol for a pivotal study of patients with acquired antithrombin deficiencies in cardiac surgery. ❋ Unknown (2010)
"The optimal dosing of unfractionated heparin should maintain the safety profile of fondaparinux but achieve adequate antithrombin effect to prevent catheter thrombus [blood clots]," the authors write. ❋ Unknown (2010)
The Framingham-based developer of therapeutic proteins produced through transgenic animal technology said the improved financial preformance was due to the recognition of non-cash revenue associated with regaining rights to ATryn, a recombinant human antithrombin from its former partner. ❋ Unknown (2010)
Altered skin perfusion, reduced urine output alterations in coagulation parameters, increases D-dimers, low protein C, low antithrombin, increased prothrombin time/activated partial thromboplastin time unexplained alterations in mental status ❋ Shabeelpn (2010)
ATryn®, GTC's recombinant human antithrombin, has been approved for use in the United States and Europe. ❋ Unknown (2010)
Building upon the 2009 FDA approval of ATryn®, GTC is collaborating with its US commercialization partner, Lundbeck Inc., to develop a protocol for a pivotal study of patients with acquired antithrombin deficiencies in cardiac surgery. ❋ Unknown (2010)
